Aspire to ASCENT: Real-world outcomes from patients with metastatic triple-negative breast cancer (mTNBC) treated with Sacituzumab govitecan (Saci) in a single academic institution

被引：1
|
作者：
Walsh, E. M.
Klar, M. [1 ]
Abuhadra, N. [1 ]
Robson, M. [1 ]
Drago, J. [1 ]
机构：
[1] Evelyn H Lauder Breast Ctr, Breast Med Serv, Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
419P
引用
收藏
页码：S359 / S359
页数：1
相关论文
共 50 条
  • [21] Assessment of sacituzumab govitecan (SG) in patients (pts) with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)
    Hegewisch-Becker, S.
    Loirat, D. L.
    Punie, K.
    Bardia, A.
    Dieras, V
    Dalenc, F.
    Diamond, J. R.
    Fontaine, C.
    Wang, G.
    Rugo, H. S.
    Hurvitz, S. A.
    Kalinsky, K.
    O'Shaughnessy, J.
    Carey, L. A.
    Loibl, S.
    Gianni, L.
    Piccart, M.
    Hong, Q.
    Phan, S.
    Itri, L. M.
    Cortes, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 133 - 133
  • [22] Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
    Joyce O’Shaughnessy
    Adam Brufsky
    Hope S. Rugo
    Sara M. Tolaney
    Kevin Punie
    Sagar Sardesai
    Erika Hamilton
    Delphine Loirat
    Tiffany Traina
    Roberto Leon-Ferre
    Sara A. Hurvitz
    Kevin Kalinsky
    Aditya Bardia
    Stephanie Henry
    Ingrid Mayer
    Yanni Zhu
    See Phan
    Javier Cortés
    Breast Cancer Research and Treatment, 2022, 195 : 127 - 139
  • [23] Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
    O'Shaughnessy, Joyce
    Brufsky, Adam
    Rugo, Hope S.
    Tolaney, Sara M.
    Punie, Kevin
    Sardesai, Sagar
    Hamilton, Erika
    Loirat, Delphine
    Traina, Tiffany
    Leon-Ferre, Roberto
    Hurvitz, Sara A.
    Kalinsky, Kevin
    Bardia, Aditya
    Henry, Stephanie
    Mayer, Ingrid
    Zhu, Yanni
    Phan, See
    Cortes, Javier
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 195 (02) : 127 - 139
  • [24] Real-world activity of sacituzumab govitecan for metastatic breast cancer
    Morganti, S.
    Kusmick, R.
    Hughes, M. E.
    Braso-Maristany, F.
    Smith, K.
    Tarantino, P.
    Vega Leon, M. D. R.
    Grinda, T.
    Pardo, F.
    Dvir, K.
    Suggs, G.
    Buck, S.
    Skeffington, M.
    Garrido-Castro, A. C.
    Parsons, H.
    Sammons, S.
    Prat, A.
    Lin, N.
    Tolaney, S. M.
    Giordano, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S382 - S382
  • [25] Understanding real-world treatment and outcomes in patients diagnosed with metastatic triple negative breast cancer (mTNBC).
    Skinner, Karen E.
    Walker, Mark S.
    Haiderali, Amin
    Schwartzberg, Lee Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Exposure-response analyses of sacituzumab govitecan (SG) efficacy and safety in patients (pts) with metastatic triple-negative breast cancer (mTNBC).
    Singh, Indrajeet
    Sathe, Abhishek G.
    Singh, Pratap
    Diderichsen, Paul M.
    Fauchet, Floris
    Maringwa, John
    Pierrillas, Philippe
    Phan, See-Chun
    Girish, Sandhya
    Othman, Ahmed A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
    Bardia, A.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Oliveira, M.
    Rugo, H. S.
    Brufsky, A.
    Kalinsky, K.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V. C.
    Carey, L. A.
    Gianni, L.
    Piccart, M.
    Loibl, S.
    Goldenberg, D.
    Hong, Q.
    Olivo, M. S.
    Itri, L. M.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1149 - S1150
  • [28] Biomarker Evaluation in the Phase 3 ASCENT Study of Sacituzumab Govitecan vs Chemotherapy in Patients With Metastatic Triple-Negative Breast Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 6 - 7
  • [29] Sacituzumab govitecan in Japanese patients with metastatic triple-negative breast cancer: phase 2 results of ASCENT J02
    Naito, Y.
    Nakamura, S.
    Kawaguchi, N.
    Ishida, T.
    Nakayama, T.
    Yamamoto, Y.
    Masuda, N.
    Matsumoto, K.
    Kogawa, T.
    Sudo, K.
    Shimomura, A.
    Lai, C.
    Zhang, D.
    Iwahori, Y.
    Gary, D.
    Huynh, D.
    Iwata, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1326 - S1326
  • [30] Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Mayer, I. A.
    Vahdat, L. T.
    Tolaney, S. M.
    Isakoff, S. J.
    Diamond, J. R.
    O'Shaughnessy, J.
    Moroose, R. L.
    Santin, A. D.
    Abramson, V. G.
    Shah, N. C.
    Rugo, H. S.
    Goldenberg, D. M.
    Sweidan, A. M.
    Iannone, R.
    Washkowitz, S.
    Sharkey, R. M.
    Wegener, W. A.
    Kalinsky, K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08): : 741 - 751
12345